Insulin-like growth factor-binding protein-3 potentiates epidermal growth factor action in MCF-10A mammary epithelial cells - Involvement of p44/42 and p38 mitogen-activated protein kinases

被引:72
作者
Martin, JL [1 ]
Weenink, SM [1 ]
Baxter, RC [1 ]
机构
[1] Univ Sydney, Royal N Shore Hosp, Kolling Inst Med Res, St Leonards, NSW 2065, Australia
关键词
D O I
10.1074/jbc.M210739200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Insulin-like growth factor-binding protein-3 (IGFBP-3) is inhibitory to the growth of many breast cancer cells in vitro; however, a high level of expression of IGFBP-3 in breast tumors correlates with poor prognosis, suggesting that IGFBP-3 may be associated with growth stimulation in some breast cancers. We have shown previously in MCF-10A breast epithelial cells that chronic activation of Ras-p44/42 mitogen-activated protein (MAP) kinase confers resistance to the growth-inhibitory effects of IGFBP-3 (Martin, J. L., and Baxter, R. C. (1999) J. Biol Chem. 274, 16407-16411). Here we show that, in the same cell line, IGFBP-3 potentiates DNA synthesis and cell proliferation stimulated by epidermal growth factor (EGF), a potent activator of Ras. A mutant of IGFBP-3, which fails to translocate to the nucleus and has reduced ability to cell-associate, similarly enhanced EGF action in these cells. By contrast, the structurally related IGFBP-5, which shares many functional features with IGFBP-3, was slightly inhibitory to DNA synthesis in the presence of EGF. IGFBP-3 primes MCF-10A cells to respond to EGF because pre-incubation caused a similar degree of EGF potentiation as co-incubation. In IGFBP-3-primed cells, EGF-stimulated EGF receptor phosphorylation at Tyr-1068 was increased relative to unprimed cells, as was phosphorylation and activity of p44/42 and p38 AMY kinases, but not Akt/PKB. Partial blockade of the p44/42 and p38 MAP kinase pathways abolished the potentiation by IGFBP-3 of EGF-stimulated DNA synthesis. Collectively, these findings indicate that IGFBP-3 enhances EGF signaling and proliferative effects in breast epithelial cells via increased EGF receptor phosphorylation and activation of p44/42 and p38 MAP kinase signaling pathways.
引用
收藏
页码:2969 / 2976
页数:8
相关论文
共 50 条
[11]   Signaling through the Smad pathway by insulin-like growth factor-binding protein-3 in breast cancer cells -: Relationship to transforming growth factor-β1 signaling [J].
Fanayan, S ;
Firth, SM ;
Baxter, RC .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (09) :7255-7261
[12]   Growth inhibition by insulin-like growth factor-binding protein-3 in T47D breast cancer cells requires transforming growth factor-β (TGF-β) and the type II TGF-β receptor [J].
Fanayan, S ;
Firth, SM ;
Butt, AJ ;
Baxter, RC .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (50) :39146-39151
[13]   Development of resistance to insulin-like growth factor binding protein-3 in transfected T47D breast cancer cells [J].
Firth, SM ;
Fanayan, S ;
Benn, D ;
Baxter, RC .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1998, 246 (02) :325-329
[14]   Adenoviral-mediated expression of human insulin-like growth factor-binding protein-3 [J].
Firth, SM ;
Ganeshprasad, U ;
Poronnik, P ;
Cook, DI ;
Baxter, RC .
PROTEIN EXPRESSION AND PURIFICATION, 1999, 16 (01) :202-211
[15]   Structural determinants of ligand and cell surface binding of insulin-like growth factor-binding protein-3 [J].
Firth, SM ;
Ganeshprasad, U ;
Baxter, RC .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (05) :2631-2638
[16]   Mutagenesis of basic amino acids in the carboxyl-terminal region of insulin-like growth factor binding protein-5 affects acid-labile subunit binding [J].
Firth, SM ;
Clemmons, DR ;
Baxter, RC .
ENDOCRINOLOGY, 2001, 142 (05) :2147-2150
[17]   RETINOID MODULATION OF INSULIN-LIKE GROWTH FACTOR-BINDING PROTEINS AND INHIBITION OF BREAST-CARCINOMA PROLIFERATION [J].
FONTANA, JA ;
BURROWSMEZU, A ;
CLEMMONS, DR ;
LEROITH, D .
ENDOCRINOLOGY, 1991, 128 (02) :1115-1122
[18]  
Grill CJ, 2000, J CELL PHYSIOL, V183, P273, DOI 10.1002/(SICI)1097-4652(200005)183:2<273::AID-JCP14>3.0.CO
[19]  
2-J
[20]   Molecular mechanisms underlying ErbB2/HER2 action in breast cancer [J].
Harari, D ;
Yarden, Y .
ONCOGENE, 2000, 19 (53) :6102-6114